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CHAPTER 1. INTRODUCTION 
 
1. Statement of the problem and objectives 
 Porcine circovirus (PCV) is a single stranded, covalently closed, circular, DNA virus 
that was first identified as a cell culture contamination (Tischer et al., 1974). Subsequently, 
research studies have shown that PCV was widespread in the pig population and non-
pathogenic (Tischer et al., 1986; Allan et al., 1995; Tischer et al., 1995). In 1991, a severe 
wasting syndrome in pigs was observed in Canada (Harding and Clark, 1997), and in the 
United States and Europe shortly thereafter (Daft et al., 1996; LeCann et al., 1997). PCV was 
found associated with the new syndrome (Ellis et al., 1998), but was shown to exhibit less 
than 80% sequence homology with the previously described PCV, indicating a new genotype 
(Meehan et al., 1998). Today, PCV is divided into two distinct genotypes: the non-
pathogenic PK-15 cell line associated PCV type 1 (PCV1), and the pathogenic disease 
causing PCV type 2 (PCV2) (Meehan et al., 1998). Retrospective studies have since shown 
that PCV2 antigen was identified as early as 1962 in tissues from a pig in Northern Germany 
(Jacobsen et al., 2009), and PCV2-associated microscopic lesions were identified in archived 
tissues as early as 1985 in Spain (Rodríguez-Arrioja et al., 2003). PCV2 can be further 
subdivided into PCV2a and PCV2b (Olvera et al., 2006), and is present in all major pork 
producing countries.  
 Since the early 1990’s, PCV2 has been associated with a number of disease 
manifestations including post-weaning multisystemic wasting syndrome (PMWS), 
respiratory disease, porcine dermatitis and nephropathy syndrome (PDNS), reproductive 
failure, enteritis, and neuropathy (Chae, 2005). The combination of all the above described 
disease manifestations is today known as porcine circovirus associated disease (PCVAD) 
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(American Association of Swine Veterinarians, 2006) which has been shown to have a major 
impact on the swine industry. Specifically, PCVAD has been shown to cause morbidity rates 
of 12.5% to 59.9% (depending on production phase and farm size) (USDA, 2006) often 
resulting in decreased average daily gain, increased time to market, and increased mortality 
rates from 3.3% to greater than 6.5% (British Pig Executive, 2006). 
 PCV2 has been shown to be shed in high quantities through feces, nasal secretions, 
oral secretions, and urine (Shibata et al., 2003; Chung et al., 2005; Segalés et al., 2005; 
Caprioli et al., 2006). Presence of PCV2 in these secretions and excretions has been shown to 
facilitate horizontal transmission when PCV2 naïve contact animals were comingled with 
PCV2-infected pigs (Bolin et al., 2001; Patterson et al., 2010a). In addition, the ability of 
PCV2 to cross the zona pellucida and infect oocytes (Bielanski et al., 2004; Mateusen et al., 
2004), the ability of PCV2 to cross the placenta and infect fetuses (Nielsen et al., 2004; Park 
et al., 2005; Madson et al., 2009b), and the ability of PCV2 to spread intrauterine and infect 
fetuses (Pensaert et al., 2004) potentially allows for vertical transmission. In support of this, 
in several experimental inoculation studies using pregnant breeding animals, vertical 
transmission was achieved (Nielsen et al., 2004; Park et al., 2005; Madson et al., 2009b). All 
of the above studies add to the body of evidence that PCV2 is not only widespread, but can 
also be transmitted through many routes. 
Due to the ubiquitous nature of PCV2 and the economic impact of PCVAD, several 
vaccines have been developed to combat this virus. There are currently four vaccines 
commercially available in North America: 1) Ingelvac® CircoFLEXTM (Boehringer 
Ingelheim Vetmedica Inc.) is a subunit vaccine that is based on the PCV2 capsid protein 
expressed in baculovirus and is licensed for use as a single dose vaccine in pigs 3 weeks and 
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older in the United States. 2) CircumventTM PCV (Merck Animal Health) is also a subunit 
vaccine based on the PCV2 capsid protein expressed in baculovirus and is licensed as a two 
dose vaccine in pigs 3 weeks and older in the United States. 3) FosteraTM PCV (Pfizer 
Animal Health Inc.) is a chimeric PCV1-2 vaccine with the PCV2 capsid gene expressed in 
the backbone of PCV1 and is licensed for use as a single dose vaccine in pigs 3 weeks and 
older in the United States. 4) Circovac® (Merial Inc.) is an inactivated PCV2 vaccine 
licensed for use as a single dose vaccine in 3 week old pigs and as a two dose vaccine in 
healthy breeding age females. The Circovac® vaccine is currently not available in the United 
States, but is available in Canada and Mexico. In addition, several experimental live PCV2 
vaccines have been developed. Live vaccines are currently not commercially available, but 
could be advantageous as they could induce a strong cellular immune response and thus 
potentially providing better protection against PCVAD compared to inactivated vaccines. 
PCV2 is spread vertically from the dam to the fetus and has been found associated 
with reproductive failure and reduced litter sizes. However, currently available vaccines are 
not licensed to protect against vertical PCV2 transmission and reproductive failure. 
Therefore, the main objective of our first study was to determine if inactivated commercial or 
experimental live PCV2 vaccines given in one or two dose administrations could minimize or 
even prevent PCV2 transmission from the dam to the fetus.  
PCV2 is also spread horizontally among pigs leading to PCV2 viremia and potentially 
PCVAD, and has been shown to be spread to naïve contact animals between 1 and 42 days 
after challenge of a source population (Bolin et al., 2001). However, no study had yet 
determined if chronically PCV2 infected pigs can transmit PCV2 horizontally to naïve 
contact animals. PCV2 vaccination has been shown to be effective in preventing or 
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minimizing PCV2 infection and PCVAD in growing pigs, and vaccinating nursery and 
grower age pigs have been monitored for 21 days (Opriessnig et al., 2009; Shen et al., 2010b; 
Sinha et al., 2010; Liu et al., 2011; Beach et al., 2010; Xujie et al., 2011), however no study 
had yet monitored the long-term efficacy of vaccination. Therefore, the main objectives of 
our second study were to determine if PCV2 is transmissible to naïve contact pigs 140 days 
after initial challenge and if PCV2 vaccination is beneficial in this scenario. 
 
2. Thesis Organization 
The present thesis has been prepared in an alternate manuscript format. The thesis 
contains an introduction, a literature review, two separate scientific manuscripts, and a 
conclusion. References for the introduction, literature review, and the conclusion are cited at 
the end of the thesis in the references cited section.  
The first manuscript describes the effect of PCV2 vaccination on breeding age 
females and intrauterine transmission of PCV2 and is currently in preparation for publication. 
The second manuscript describes the transmission of PCV2 to PCV2 naïve contact animals 
and the long-term efficacy of PCV2 vaccination in growing age pigs is currently in 
preparation for publication.  
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CHAPTER 2. LITERATURE REVIEW 
 
1. Taxonomy and organization 
Porcine circovirus (PCV) was first identified in 1974 as a contaminate of the 
continuous porcine kidney cell line PK-15 ATCC CCL-33 (Tischer et al., 1974) and was later 
shown to be non-pathogenic in swine (Tischer et al., 1986; Allan et al., 1995). In 1998, a new 
genotype of PCV was identified in swine in North America and Europe in association with 
wasting disease (Morozov et al., 1998; Allan et al., 1998b; Allan et al., 2000). The new PCV 
was designated as PCV type 2 (PCV2) and the original genotype was designated as PCV type 
1 (PCV1) (Meehan et al., 1998; Allan et al., 1998a). Together, PCVs are classified in the 
family Circoviridae and the genus Circovirus (Todd et al., 2005).  
PCVs consist of two major open reading frames (ORFs), though 11 potential ORFs 
exist in the PCV genome (Hamel et al., 1998). ORF1 encodes for the viral replicase protein 
and ORF2 encodes for the viral capsid protein (Mankertz et al., 1998; Nawagitgul et al., 
2000; Cheung, 2003). A third ORF, ORF3, plays a role in apoptosis (Liu et al., 2006b) and, 
more recently, has been indicated to play a role in systemic spread of infection by 
recruitment of macrophages and initiating early release of PCV2 from infected cells 
(Karuppannan et al., 2011). Mutation of ORF3 has been shown to decreased PCV2 viremia 
in mice (Karuppannan et al., 2009) and pigs (Juhan et al., 2009); however no differences in 
gross or microscopic lesions were noted (Karuppannan et al., 2009; Juhan et al., 2010).  
Since first recognized in 1998, several subtypes of PCV2 have been identified. The 
two main subtypes include PCV2a, which until approximately 2005, was the only subtype 
found in North America, and PCV2b which has become the most prevalent subtype 
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worldwide (Gagnon et al., 2007; Allan et al., 2007; Patterson et al., 2010a). PCV2a and 
PCV2b differ in genome length (PCV2a has 1768 nucleotides and PCV2b has 1767 
nucleotides) (Olvera et al., 2006) and in their sequence with the most recognizable difference 
found in a 6 amino acid stretch known as the signature motif located in ORF2 (Cheung et al., 
2007). Initial results from the field indicated that PCV2b was more pathogenic than PCV2a; 
however experimental studies were unable to confirm this under controlled conditions 
(Opriessnig et al., 2007b; Fort et al., 2008; Harding et al., 2010). 
 
2. Disease manifestations 
PCV2 was first associated with a chronic wasting syndrome in young pigs (Ellis et 
al., 1998), termed post-weaning multisystemic wasting syndrome (PMWS), originally 
described in 1991 (Harding and Clark, 1997). Since this time, PCV2 has been associated with 
a series of diseases currently termed porcine circovirus associated disease (PCVAD). This 
includes PMWS or systemic disease, porcine dermatitis and nephropathy syndrome (PDNS), 
respiratory disease, enteritis, reproductive failure, and possibly neuropathy (Gillespie et al., 
2009). 
 
2.1. Post-weaning multisystemic wasting syndrome (PMWS) or systemic disease 
Clinical symptoms in PMWS affected pigs include progressive weight loss, jaundice, 
lethargy, unthriftiness, and diarrhea (Harding et al., 1998). In addition, other less common 
symptoms such as lameness, sudden death, heart failure, and intestinal torsion have also been 
reported. Consistent gross lesions found in affected pigs include generalized 
lymphadenopathy and often lungs are mottled tan and fail to collapse. Frequently seen 
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microscopic lesions in lymphoid tissues include depletion of lymphoid follicles with 
histiocytic replacement. Macrophages can contain intracytoplasmic inclusion bodies (Sorden, 
2000). Additional microscopic lesions can include lymphohistiocytic to granulomatous 
inflammation in other organ systems such as lungs, liver, intestines, and kidneys (Sorden, 
2000). Typically, PCV2 antigen can be demonstrated in high levels in tissues with 
immunohistochemistry (IHC) or in-situ hybridization (ISH) (Opriessnig et al., 2007a). 
PMWS can lead to mortality rates around 10% or higher in herds (Harding et al., 1997) and 
most commonly affects animals between 7 and 16 weeks of age in North America and 
between 5 and 12 weeks of age in Europe (Gillespie et al., 2009).  
 
2.2. Porcine dermatitis and nephropathy syndrome (PDNS) 
PDNS was first associated with PCV2 in 2000 and is commonly characterized by 
raised purple skin lesions with black centers located on the hind quarters, fever, and lethargy 
(Rosell et al., 2000). At necropsy, animals with PDNS will have enlarged kidneys with 
petechial hemorrhages (Rosell et al., 2000) which is thought to be due to deposition of a large 
amount of antigen:antibody complexes throughout the vasculature. Microscopic lesions 
consist of vasculitis and glomerulonephritis (Rosell et al., 2000). Pigs are most commonly 
affected with PDNS between the ages of 12 and 16 weeks (Gresham et al., 2000). 
 
2.3. PCV2-associated respiratory disease 
PCV2-associated respiratory disease is often associated with the porcine respiratory 
disease complex (PRDC) (Harms et al., 2002). Common symptoms include sneezing, 
respiratory distress, nasal discharge, lethargy, decreased growth rate, and fever. 
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Histopathologically, animals with PCV2-associated respiratory disease have 
bronchointerstitial pneumonia, marked cellular infiltrates composed mainly of macrophages, 
necrotizing bronchiolitis, and peribronchiolar fibrosis (Harms et al., 2002; Chae, 2005). 
PCV2-associated respiratory disease usually affects pigs between 8 and 26 weeks of age. 
 
2.4. PCV2-associated enteritis 
PCV2-associated enteritis was first reported in 2004 (Kim et al., 2004b). Clinical 
signs include reduced growth rates, diarrhea, unthriftiness, and increased mortality rates. 
Gross lesions include thickening of the mucosa in the ileum and enlarged mesenteric lymph 
nodes (Kim et al., 2004b). Histopathologically, PCV2-associated enteritis is characterized by 
infiltration of macrophages and mononuclear cells in the mucosa and submucosa of the small 
and large intestines, granulomatous enteritis, and lymphoid depletion with histocytic 
replacement of Peyer’s patches (Jensen et al., 2006). To confirm PCV2 involvement, IHC on 
the intestines can be used to detect antigen in macrophages (Kim et al., 2004a). Enteritis with 
PCV2 involvement often affects animals between 8 and 16 weeks of age (Gillespie et al., 
2009).  
 
2.5. PCV2-associated reproductive failure 
PCV2-associated reproductive failure was first noted in 1999 in Canada and is 
characterized by abortions and increased numbers of still-borns and mummified fetuses as 
well as weak-born fetuses in full term litters (West et al., 1999; Madson et al., 2009b). 
Common histopathological lesions include myocardial necrosis with infiltration of 
macrophages in still-born and mummified fetuses. Abundant PCV2 antigen can typically be 
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found in the myocardium and tonsils of affected animals by IHC (Madson et al., 2009c). This 
manifestation is most commonly associated with gilts or young parity sows, thus affecting 
start-up operations more than stable operations (Mikami et al, 2005). 
 
2.6. PCV2-associated neuropathy 
An association of PCV with congenital tremors was first reported in 1994 when sows 
were infected with a PCV detected in a fetus with congenital tremors and farrowed litters that 
all had congenital tremors (Hines et al., 1994). Since this first link between PCV and 
congenital tremors, this disease manifestation has been reproduced in newborn piglets (Choi 
et al., 2002), but in some studies, when tissues from fetuses with congenital tremors were 
tested, no PCV2 was detected (Kennedy et al., 2003; Ha et al., 2005). Microscopic lesions 
associated with congenital tremors include lymphohistiocytic vasculitis in brain tissues, 
meningitis, and encephalitis (Correa et al., 2007). 
 
3. PCV2 Transmission 
PCV2 is widespread and present in nearly all major pork producing countries 
(Patterson et al., 2010a). Transmission of PCV2 has been shown to occur by both horizontal 
and vertical routes. 
 
3.1. Horizontal Transmission 
PCV2 DNA has been detected in tonsillar and fecal swabs (Bolin et al., 2001; 
Caprioli et al., 2006), in nasal and fecal swabs (Bolin et al., 2001; Harms et al., 2001; Shibata 
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et al., 2003; Patterson et al., 2010b), tracheobronchial swabs, and urinary swabs (Segalés et 
al., 2005). In addition, viable PCV2 has been recovered from nasal and fecal swabs (Magar et 
al., 2000; Krakowka et al., 2000). Samples in these studies were collected between 1 and 70 
days post inoculation (dpi), and PCV2 DNA or viable PCV2 could be detected in a variety of 
time points (Shibata et al., 2003; Patterson et al., 2010b). PCV2 DNA has also been shown to 
be shed in the colostrum of sows (Shibata et al., 2006). A study on the effect of disease status 
on PCV2 shedding indicated that more DNA was detected in feces of nursery pigs suffering 
from PCVAD compared to clinically healthy pigs (McIntosh et al., 2008). All these studies 
demonstrate that PCV2 can be transmitted through a wide variety of secretions and 
excretions for extended periods of time at varying quantities. 
 
3.2. Vertical Transmission 
a. PCV2 infection in boars. PCV2 can be demonstrated in testes and accessory glands 
of boars (Opriessnig et al., 2006). In addition, several studies have detected PCV2 in semen 
from infected boars (Larochelle et al., 2000; Kim et al., 2003; McIntosh et al. 2006; Madson 
et al., 2008). PCV2 can be shed for periods ranging from 6 days (Madson et al., 2008) to 27 
weeks (McIntosh et al., 2006) in serum and semen from experimentally infected or naturally 
infected boars. In addition, PCV2 is more often detected in the non-cell fraction of semen 
and in the seminal fluid than the sperm fraction (Kim et al., 2003). The effect of PCV2 
infection on semen quality has also been studied and PCV2 DNA was not associated with 
changes in semen morphology (McIntosh et al., 2006; Madson et al., 2008). 
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b. PCV2 infection in sows. PCV2 can infect breeding age females resulting in 
subclinical infections (Madson et al., 2011). While sows often do not show clinical signs of 
disease, if PCV2 viremia occurs during pregnancy PCV2 can cross the placenta and infect 
the fetuses. Under field conditions, natural infection of pregnant sows with PCV2 has 
resulted in late term abortions characterized by increased numbers of mummified fetuses 
which all had abundant PCV2 antigen in the myocardium (West et al., 1999) as well as 
increased mortality rates in live-born piglets (Calsamiglia et al., 2007). Pregnant sows that 
have been experimentally infected intranasally with PCV2 had increased numbers of still-
borns and mummified fetuses (Park et al., 2005). In addition, reproductive failure was 
experimentally reproduced by spiking semen with PCV2 and artificially inseminating naïve 
sows (Madson et al., 2009b).  
 
c. PCV2 infection in fetuses. After intranasal PCV2 infection of sows, fetuses had 
detectable PCV2 antigen and DNA in lymphoid tissues and other organs indicating PCV2 
replication (Park et al., 2005). In fetuses, PCV2 targets myocardial tissues for replication 
leading to vasculitis and cardiac failure in some cases. PCV2 antigen is found in myocardial 
tissues and tonsils of still-born and mummified fetuses (Madson et al., 2009c). In one study, 
healthy live-born piglets in the United States and Mexico were tested for presence of PCV2 
viremia and PCV2-specific antibodies prior to colostrum uptake, and 39.9% and 21.4% 
respectively were positive (Shen et al., 2010a) indicating that vertical transmission of PCV2 
is not a rare event. 
 
4. Prevention through biosecurity and farm management 
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4.1. Biosecurity and farm management 
Several publications have listed ideal biosecurity and farm management practices for 
decreasing the spread of disease (Moore, 1992; Madec et al., 1999; Stokes et al., 2010). The 
following summarizes the most important farm management and biosecurity practices that 
can minimize any virus spread including PCV2: introduction of a quarantine period, 
following strict all-in all-out practices with proper cleaning and disinfecting between groups, 
only using semen from boars of known health status for artificial insemination (AI), 
minimizing visitors to a facility, disinfecting trailers prior to shipment, and removing sick 
animals quickly. In addition, dead animals should be removed from the facility in a timely 
manner and necropsied for evaluation of cause of death.  
 
4.2. PCV2 disinfectants 
The effect of disinfectants on PCV2 viability has been evaluated by several research 
groups. An in-vitro study determined that potassium peroxomonosulfate, sodium 
hypochlorite, and sodium hydroxide, but not formalin were able to inactivate PCV2 (Kim et 
al., 2009a). In other in-vitro studies, products containing aldehydes or quaternary ammonium, 
but not iodine or phenolytic compounds were able to reduce PCV2 viability (Royer et al., 
2001; Martin et al., 2008). When four disinfectants with known in-vitro capabilities to 
inactivate PCV2 were applied under field conditions, all four were capable of decreasing but 
not totally eliminating PCV2 DNA (Patterson et al., 2011). PCV2 naïve animals remained 
PCV2 negative after being exposed to the residual DNA (Patterson et al., 2011). These 
studies indicate that PCV2 is relatively stable, but that the use of certain disinfectants could 
decrease the viability of PCV2 to a non-infectious level. 
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5. Prevention through vaccination 
Since PCV2 was first associated with clinical disease, several experimental PCV2 
vaccines have been developed. This section will describe the development of experimental 
vaccines, commercially available vaccines, and studies on vaccine efficacy.  In 2003, the 
documentation of the development of several candidate PCV2 vaccines began. Initial 
publications showed the PCV2 capsid protein (ORF2) as the most immunogenic portion of 
the viral genome (Blanchard et al., 2003; Nawagitgul et al., 2000), which has become a main 
target for PCV2 vaccine production. 
 
5.1. Vaccine types 
Several types of PCV2 vaccines have been developed and tested in both the swine 
and mouse model. These include DNA vaccines, subunit vaccines, chimeric vaccines, and 
divalent vaccines. 
 
a. DNA vaccines. In 2004, a PCV2 isolate was attenuated by passaging it 120 times in 
cell culture (Fenaux et al., 2004b). Comparison of the genomes of the original virus and the 
virus after the 120th passage showed two point mutations in the capsid protein which 
increased viral growth in-vitro, but caused attenuation in-vivo (Fenaux et al., 2004b) 
indicating the virus could potentially be used as an attenuated-live vaccine. When the PCV2 
capsid protein was expressed in a DNA vector, it induced PCV2-specific antibodies in the 
mouse model (Kamstrup et al., 2004). In addition, expression of the PCV2 capsid protein 
bound to ubiquitin induced higher levels of T-helper 1 cellular response and PCV2-specific 
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antibodies in vaccinated mice in comparison to mice vaccinated with the PCV2 capsid alone 
(Fu et al., 2011), indicating that binding ubiquitin to a PCV2 vaccine could initiate a stronger 
immune response. Vaccination with small hairpin RNAs (shRNAs) has also been shown to 
decrease the levels of PCV2 DNA and protein synthesis in vaccinated challenged mice (Liu 
et al., 2006a) and vaccination with porcine parvovirus-like particles carrying PCV2 
immunodominant epitopes was capable of eliciting a humeral immune response (Pan et al., 
2008).  
Despite ORF2 being considered the immunogenic portion of PCV2, several studies 
have attempted to utilize other ORFs of PCV2 to determine their potential as vaccine 
candidates. Using the prime-boost theory in which one vector is utilized initially to prime the 
immune response and boosted by vaccination with a second vector to produce higher levels 
of T-cell responses, the immune system of mice was primed with the naked modified 
vaccinia virus ankara vector and then immunized with any combination of the three ORFs of 
PCV2 cloned into the vector (Aravindaram et al., 2009). Increasing levels of T-helper 1 cells 
were found in vaccinated mice, especially in mice that had been vaccinated with the 
combination of ORF2 and ORF3 or with all three ORFs (Aravindaram et al., 2009). In 
another study, vaccination of mice with plasmids expressing ORF2 along with either ORF1 
or ORF3 resulted in development of humeral (neutralizing antibodies) and cellular (T-helper 
1) immune responses to challenge in both groups (Shen et al., 2009). Finally, vaccination of 
mice with DNA encoding one of six ORFs gave different cytokine profiles based on the ORF 
used (An et al., 2008). For example, vaccination with ORF3 induced a lethal amount of 
tumor necrosis factor alpha (TNF-α) in several vaccinated mice, vaccination with ORF2 
induced high levels of interleukin-10 (IL-10, related to humeral immunity and T-helper 2 
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responses), and vaccination with ORF1 induced high levels of interferon gamma (IFN-γ) and 
IL-13 (related to T-helper 1 responses) (An et al., 2008). These studies could give researchers 
an idea on which ORFs to use to stimulate a specific immune response against PCV2 
infections, though similar studies would need to be carried out in the swine model to verify 
these results.  
 
b. Subunit vaccines. Several vaccines have been developed by cloning a PCV2 
protein into a vector such as adenovirus or baculovirus, thereby developing subunit vaccines. 
In 2003, vaccination with PCV2 ORF2 expressed in a baculovirus vector induced a more 
effective immune response than DNA vaccination with ORF1 of PCV2 and ORF2 of PCV2 
in the swine model (Blanchard et al., 2003). A vaccine based on the PCV2 capsid protein 
expressed in an adenovirus vector has been shown to prevent PCVAD and decrease lesions 
and viremia in comparison to control groups (Wang et al., 2007). In addition, vaccination 
with the PCV2 capsid protein expressed in a baculovirus vector induced PCV2 specific 
lymphocyte responses in vaccinated pigs (Fan et al., 2007), and a baculovirus-based PCV2 
capsid protein vaccine expressed in a Trichoplusia ni larvae induced PCV2 protection by 
reducing PCV2 viremia and shedding in challenged pigs (Perez-Martin et al., 2010). A 
vaccine based on the PCV2 capsid protein cloned into the Bordetella bronchoseptica aroA 
vector led to development of a PCV2-specific antibody response and a decrease of PCV2 
DNA in lymph nodes of vaccinated mice and pigs (Kim et al., 2009b). These are examples of 
the development of candidate subunit vaccines for induction of a PCV2-specific immune 
response in pigs. Currently, there are three commercially available subunit vaccines available 
that are highly effective against PCV2 in pigs. 
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Subunit vaccines in the adenovirus vector have also been evaluated in the mouse 
model. The shRNAs expressed in an adenovirus vector decreased PCV2 replication both in-
vitro and in-vivo in the mouse model (Feng et al., 2008). Interestingly, linking IFN-γ with the 
PCV2 capsid protein through a hydrophobic peptide in an adenovirus vector led to stronger 
PCV2-specific antibody responses in comparison to mice that had been immunized with the 
PCV2 capsid protein expressed in the adenovirus vector without IFN-γ (Genmei et al., 2011). 
This indicates that IFN-γ could help elicit a stronger immune response and could be used to 
increase the efficacy of the vaccine. In one study, the capsid protein of PCV2 was cloned into 
an adenovirus vector and used to immunize mice which led to development of PCV2-specific 
antibodies (Wang et al., 2006). Finally, expression of the PCV2 capsid protein in the 
Lactococcus lactis vector used for oral vaccination of mice resulted in a strong PCV2-
specific antibody response (Wang et al., 2008) indicating this could be a possible oral 
vaccine candidate. Similar to the DNA vaccines, studies done in mice would need to be 
verified in the swine model. 
 
c. Chimeric vaccines. Chimeric vaccines, using the capsid protein of one PCV and the 
backbone of another, have also been created for protection against PCVAD. In 2003, 
chimeric PCV1-2 (capsid protein of PCV2 cloned into the backbone of PCV1) and PCV2-1 
(capsid protein of PCV1 cloned into the backbone of PCV2) DNA clones were developed 
and tested in the pig model (Fenaux et al., 2003). PCV1-2 chimeric DNA clones, but not 
PCV2-1 chimeric DNA clones, elicited PCV2-specific antibodies and had significantly less 
severe gross and microscopic lesions in comparison to animals inoculated with PCV2 
infectious DNA clones (Fenaux et al., 2003). Similar to the results seen in the pig studies, a 
17 
 
PCV1-2 DNA clone has also been shown to induce humeral immunity in mice (Yi et al., 
2008). To further determine the ability of PCV1-2 to induce protective immunity in the swine 
model, pigs were subsequently challenged with PCV2 after vaccination (Fenaux et al., 
2004a). Vaccinated pigs had minimal microscopic lesions, decreased PCV2 DNA load in 
lymph nodes, and no detectable PCV2 viremia, which was in contrast to non-vaccinated, 
challenged animals (Fenaux et al., 2004a). Intramuscular vaccination of pigs with a chimeric 
PCV1-2 live vaccine led to decreased PCV2 DNA in lymph nodes and lesions after challenge 
in comparison to non-vaccinated challenged pigs (Cheng et al., 2009) indicating the live 
chimeric vaccine could be effective. Although a live-attenuated PCV1-2 vaccine has been 
shown to spread to naïve contact animals, it provided protection to vaccinated and contact 
animals in a PCV2 and co-infecting pathogens triple challenge model (Opriessnig et al., 
2011a). Tagging a live chimeric PCV1-2 vaccine with an epitope tag also induced an 
immune response, and allowed for verification of vaccination through antibodies to both 
PCV2 and the tag (Beach et al., 2011). This vaccine has the potential to serve as a marked 
attenuated-live vaccine as detection of seroconversion to the tag could demonstrate vaccine 
compliance in the presence of passively-acquired antibodies against PCV2.  
 
d. Divalent vaccines. Vaccines can be used to provide protective immunity against 
not only PCV2 but to co-infecting pathogens simultaneously. Pigs vaccinated with a divalent 
vaccine containing inactivated PCV2 and porcine reproductive and respiratory syndrome 
virus (PRRSV), developed antibodies to both viruses and were protected from challenge (Jin 
et al., 2010). A similar study in mice expressing ORF2 of PCV2 and GP5 of PRRSV in an 
adenovirus vector as a candidate vaccine elicited antibody responses to both viruses (Wang et 
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al., 2009). Expression of the PCV2 capsid protein in the pseudorabies (PRV) vector (Song et 
al., 2007) and expression of a portion of PCV2 ORF1 fused with a portion of PCV2 ORF2 in 
the PRV vector (Ju et al., 2005) elicited a strong humeral immune response to both viruses in 
pigs, though animals were not subjected to challenge. Similarly, expression of the PCV2 
ORF1 and ORF2 fused protein in a PRV vector induced strong antibody responses to both 
viruses in mice, and provided protection from disease in a PRV challenge (Ju et al., 2005). 
These candidate vaccines could provide protection not only to PCV2 infection, but to two 
important swine pathogens simultaneously.  
 
5.2. Commercially available PCV2 vaccines 
In response to the severe PCVAD outbreaks in North America during 2005-2006 
several commercial PCV2 vaccines became available. Currently available globally are three 
subunit vaccines where the ORF2 of PCV2a is expressed in a baculovirus vector (Ingelvac® 
CircoFLEXTM, CircumventTM PCV, and Porcilis® PCV), one inactivated chimeric vaccine 
with ORF2 of PCV2a and ORF1 of PCV1 (FosteraTM PCV, formerly known as Suvaxyn® 
PCV), and one inactivated PCV2 vaccine (Circovac®), which is not available in the United 
States but is licensed for use in Canada and Mexico (table 1). 
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Table 1. Globally most widely utilized PCV2 vaccines. 
Vaccine 
Name Company 
Vaccine 
Type 
Age at 
Vaccination Dosage Protection 
Ingelvac® 
CircoFLEX™ 
Boehringer 
Ingelheim 
Vetmedica 
Inc. 
Subunit 3 weeks 1 
2 weeks post-
vaccination 
for 17 weeks 
CircumventTM 
PCV Merck Animal 
Health 
 
Subunit 
 
3 weeks 2 Not available 
Porcilis® PCV 3 days 1 
2 weeks post-
vaccination 
for 22 weeks 
FosteraTM 
PCV 
Pfizer 
Animal 
Health 
Chimeric 3 weeks 1 
2 weeks post-
vaccination 
for 4 months 
Circovac® Merial Inc. PCV2 
3 weeks 1 
2 weeks post-
vaccination 
for 14 weeks 
Breeding age 2 5 weeks post-parturition 
 
5.3. PCV2 vaccine efficacy under experimental conditions 
a. Naïve pigs. Since co-infections are common in the field, several recent studies have 
evaluated the efficacy of commercially available vaccines in a dual or triple challenge model 
to mimic field conditions. Suvaxyn® PCV decreased viremia and lesions in a dual challenge 
model (Opriessnig et al., 2008a) and both commercial (Suvaxyn® PCV, Ingelvac® 
CircoFLEX™, and CircumventTM PCV) and experimental vaccines were effective in a triple 
challenge model at decreasing viremia and lesions (Opriessnig et al., 2009; Shen et al., 
2010b). Additionally, one group investigated the effect of PRRSV infection at the time of 
vaccination and determined that three commercially available vaccines (Suvaxyn® PCV by 
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Fort Dodge Animal Health, Ingelvac® CircoFLEX™, and CircumventTM PCV) were 
efficacious regardless of PRRSV infection at the time of vaccination (Sinha et al., 2010). 
More recently, questions as to whether or not neonatal piglets are able to mount an effective 
immune response to vaccination have arisen. In a recent study, two commercially available 
vaccines (Suvaxyn® PCV and Ingelvac® CircoFLEX™) elicited immune responses and 
decrease viremia in piglets vaccinated at 5 days and 21 days of age (O'Neill et al., 2011) 
indicating young animals are able to mount an immune response.  
b. Conventional pigs. All of the studies in the above section were done in animals 
naïve to this virus, however since PCV2 is ubiquitous in nature, maternal antibodies are 
common in the field. In Germany, the use of Porcilis® PCV was tested in both a two dose 
administration and a one dose administration. Decreased mortality and improved growth 
performance was demonstrated for both vaccine administration protocols, though some side 
effects were noted in the two dose administration (Beek, 2008). Vaccination of pigs with a 
single dose of Porcilis® PCV resulted in strong cellular and humeral immune responses 
associated with decreased PCV2 viremia and shedding in another study (Fort et al., 2009). 
Many practitioners questioned the efficacy of PCV2 vaccination in pigs with passively 
acquired antibodies, and several studies were conducted to clarify this. PCV2 vaccination 
with Suvaxyn® PCV was highly effective in the presence of maternal antibodies (Opriessnig 
et al., 2008b). Similarly, vaccination with Porcilis® PCV was effective in the presence of 
maternal immunity and provided protection against different isolates from different 
geographical regions (Fort et al., 2008). Piglets born to sows that had been vaccinated with 
either Circovac® or Ingelvac® CircoFLEXTM and that were subsequently vaccinated with 
the same vaccine as their dam had similar antibody responses and were protected against 
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PCV2 challenge in comparison to naïve piglets that were vaccinated (Opriessnig et al., 
2010a). These experimental studies indicate that maternal antibodies do not have negative 
impacts on PCV2 vaccine efficacy. 
 
c. Breeding age animals. Vaccination or infection of sows with PCV2 increased anti-
PCV2 levels in the colostrum; however, little research has been done on the effect of 
vaccination on vertical transmission and the effect of vaccination on boars. Sows vaccinated 
with Ingelvac® CircoFLEX™ and challenged with PCV2 had decreased PCV2 viremia, but 
vaccination did not prevent transmission of PCV2 to the fetuses in-utero (Madson et al., 
2009a; Madson et al., 2009c). Under field conditions, vaccination of sows with the 
Circovac® vaccine in Polish herds led to increasingly favorable returns to estrus and 
decreased rates of abortion (Pejsak et al., 2009). Vaccination of boars led to decreased length 
of recurring infections (Alberti et al., 2011), and vaccination with Suvaxyn® PCV 
significantly decreased PCV2 shedding in semen of experimentally infected boars 
(Opriessnig et al., 2011b). Vaccination of boars with a commercially available tissue 
homogenate vaccine (CircoPrime, Komipharm International Company Ltd.) also decreased 
quantity of viral shedding in semen of experimentally infected boars (Seo et al., 2011). These 
studies indicate that vaccination of breeding age animals could be used to decrease, but not 
prevent vertical PCV2 transmission.  
 
5.4. PCV2 vaccine efficacy under field conditions.  
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Vaccine efficacy in all phases of production is commonly evaluated by comparing 
average daily gain, feed conversion ratios, mortality rates, and morbidity rates between 
vaccinated and non-vaccinated pigs. 
 
 a. Suckling pigs. As mentioned in the previous section, vaccination of breeding age 
females provides improved passive protection to piglets during the suckling phase. In the 
field, piglets are often vaccinated at 3 weeks of age which does not provide protection during 
the suckling phase. To account for this, vaccination of sows with Circovac® resulted in 
increased health and performance of piglets in comparison to non-vaccinated sow litters 
(Joisel et al., 2008). These results were confirmed by a different study where again decreased 
mortality of piglets prior to weaning was seen in response to sow vaccination (Pejsak et al., 
2010).  
 
b. Nursery pigs. Vaccinating piglets with several commercially available vaccines 
(Circovac®, Ingelvac® CircoFLEX™, Porcilis® PCV) led to increased average daily gain 
and decreased mortality rates in comparison to non-vaccinated pigs (Liber et al., 2011; Fraile 
et al., 2011; Pejsak et al., 2010). Interestingly, nursery pigs vaccinated with CircumventTM 
PCV had decreased average daily gain compared to those vaccinated with Ingelvac® 
CircoFLEX™ (Potter et al., 2009). It is important for producers to keep in mind that 
vaccinating sows may enhance passively acquired antibody levels for piglets and decreased 
mortality rates in the suckling phase; however, vaccinating piglets in the nursery phase can 
lead to better production performances and decreased mortality rates when maternally 
derived antibodies wane.  
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c. Grow-finish pigs. PCV2 vaccination has been shown to decrease mortality and 
morbidity rates and increase average daily gain and feed conversion ratios (Jacela et al., 
2007a; Jacela et al., 2007b; Horlen et al., 2008; Takahagi et al., 2009; Paphavasit et al., 2009; 
Richthofen et al., 2009; Arnold et al., 2010; Cardinal, 2010; Haugegaard et al., 2010; Martelli 
et al., 2011; Jacela et al., 2011; Venegas-Vargas et al., 2011; Young et al., 2011). In addition, 
two dose vaccination at 5 and 7 weeks rather than 9 and 11 weeks was more effective (Jacela 
et al., 2007a), though vaccination at this later age is uncommon. A meta-analysis of all field 
cases of PCV2 vaccination showed decreased mortality and increased average daily gain with 
average daily gain differences dependent on PRRSV status of the herd (Kristensen et al., 
2011), and vaccination with Porcilis® PCV or Ingelvac® CircoFLEX™ performance results 
were dependent on the PCV2 subtype that infected the animals (Takahagi et al., 2009). In 
addition, pigs vaccinated with Ingelvac® CircoFLEX™ had decreased levels of PRDC 
(Bischoff et al., 2009; Fachinger et al., 2008). Vaccination with Ingelvac® CircoFLEX™ or 
Suvaxyn® PCV decreased PCVAD symptoms present at several farms (Kixmöller et al., 
2008; Desrosiers et al., 2009; Segalés et al., 2009). Vaccination with CircumventTM PCV 
improved overall herd performance and decreased losses in animals concurrently infected 
with PRRSV (Shelton et al., 2009). In addition, one study showed that other factors such as 
gender, birth weight, and vaccine strategy had additional effects on performance in 
association with PCV2 vaccination (Bergstrom et al., 2009). In summary, producers should 
keep in mind the differences between vaccines on different phases of production when 
deciding which vaccine to use in their herds.  
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CHAPTER 3: A LIVE-ATTENUATED AND AN INACTIVATED 
CHIMERIC PCV1-2 VACCINE ARE BOTH EFFICTIVE AT INDUCING 
A HUMERAL IMMUNE RESPONSE AND REDUCING PCV2 VIREMIA 
AND INTRAUTERINE INFECTION IN BREEDING AGE FEMALES 
A paper prepared for publication 
Michelle Hemann, Nathan M. Beach, Xiang-Jin Meng, Chong Wang, Patrick G. Halbur, and 
Tanja Opriessnig 
 
Abstract 
The objective of this study was to determine the efficacy of inactivated (one or two dose) and 
live-attenuated chimeric PCV1-2 vaccines in sows using the PCV2-spiked semen model. 
Thirty-five sows were randomly divided into six groups: negative and positive controls, one 
dose inactivated PCV1-2 vaccine challenged (1-VAC-PCV2), two dose inactivated PCV1-2 
vaccine challenged (2-VAC-PCV2), one dose live-attenuated PCV1-2 vaccine unchallenged 
(1-LIVE-VAC), and one dose live-attenuated PCV1-2 vaccine challenged (1-LIVE-VAC-
PCV2). The inactivated PCV1-2 vaccine induced higher levels of PCV2-specific antibodies 
in dams. All vaccination strategies provided good protection against PCV2 viremia in dams, 
whereas the majority of the unvaccinated sows were viremic. Four of the 35 dams became 
pregnant: a negative control, a positive control, a 2-VAC-PCV2 sow, and a 1-LIVE-VAC-
PCV2 sow. PCV2 DNA was detected in 100%, 67% and 29% of the fetuses obtained from 
the positive control, inactivated vaccinated or live-attenuated vaccinated dams. PCV2 antigen 
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in hearts was only detectable in the positive control litter (23% of the fetuses). PCV1-2 DNA 
was detected in 29% of the fetuses in the litter from the 1-LIVE-VAC-PCV2 dam. Under the 
conditions of this study, both vaccines protected against PCV2 viremia in breeding age 
animals; however, vertical transmission was not prevented.  
 
Keywords: Porcine circovirus; Breeding animals; Vaccination; Live-attenuated chimeric 
vaccine; Inactivated vaccine. 
 
Introduction 
Porcine circovirus (PCV) is a member of the Circoviridae family in the genus 
Circovirus. It is a non-enveloped, single stranded DNA virus with a circular genome. The 
genome of PCV2 contains two major open reading frames (ORFs): ORF1 encodes for a 
protein essential for viral replication, and ORF2 encodes for the capsid protein (1,2). Two 
main types of PCV have been identified: PCV type 1 (PCV1) and PCV type 2 (PCV2) which 
share approximately 83% nucleotide sequence identity in ORF1 but only 67% identity in 
ORF2 (3).  
PCV1 was first identified as a contaminate of a continuous porcine kidney cell line 
(PK-15) in 1974 (4,5). Despite being widespread in the pig population, PCV1 has been 
shown to be non-pathogenic in pigs (6,7). However, PCV2 is associated with a group of 
diseases collectively called porcine circovirus associated disease (PCVAD) including PCV2-
associated reproductive failure in mature animals (8).  
PCV2-associated reproductive failure is typically characterized by increased numbers 
of abortions, mummified and stillborn fetuses and weakborn piglets (9). Confirmation of 
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PCV2 as the causative agent of reproductive failure is done by identification of myocardial 
fibrosis, lymphoplasmacytic myocarditis, and association of PCV2 antigen with the fetal 
heart lesions by immunohistochemistry (IHC) (10). Piglet serum or fetal thoracic fluid may 
also be positive for PCV2 DNA or PCV2-specific antibodies (10). 
It has been shown that a chimeric PCV1-2 strain with the capsid gene of PCV2 in the 
backbone of the non-pathogenic PCV1 was non-pathogenic under experimental conditions. 
The inactivated commercial PCV2 vaccine “FosteraTM PCV” was recently reintroduced to 
the global market and is based on the PCV1-2 chimera. The non-pathogenic chimeric PCV1-
2 virus may also have potential for use as a live-attenuated chimeric PCV2 vaccine (11,12). 
PCV2 can be further divided into at least three subtypes. The most important subtypes 
which are prevalent worldwide include PCV2a which was the predominant strain in the pig 
population before 2000, and PCV2b which has replaced PCV2a in most herds and is 
currently the predominant PCV2 genotype in North America (13,14). One of the main 
differences between PCV2a and PCVb is in the signature motif in ORF2. Comparative 
pathogenicity studies among the two PCV2 subtypes side by side in experimentally-infected 
pigs have failed to show any differences in virulence (15,16). 
Vaccination against PCV2 has been shown to be highly effective in decreasing losses 
associated with PCVAD. There are currently several types of commercial vaccines available 
including an inactivated PCV2 vaccine for use in dams or piglets (Circovac®, Merial, Inc.), 
two subunit vaccines based on PCV2-ORF2 expressed in baculovirus for use in growing pigs 
(CircumventTM PCV, Intervet, Inc. and Ingelvac® CircoFLEXTM, Boehringer Ingelheim, 
Vetmedica, Inc.), and an inactivated chimeric PCV1-2 vaccine for use in growing pigs 
(FosteraTM PCV, Pfizer Animal Health Inc, formerly Suvaxyn® PCV2 One DoseTM from 
27 
 
Fort Dodge Animal Health). All these vaccines are based on PCV2a with differences in 
dosage and recommended timing for use of these products (8).  
All commercially available PCV2 vaccines are inactivated or subunit vaccines. 
Another type of vaccine currently in the experimental stage of development is a live-
attenuated PCV2 vaccine based on a chimeric PCV1-2. One concern with any live-attenuated 
vaccine is the development of vaccine virus viremia in immunized pigs and spread of the 
vaccine virus among pigs and herds. It has been previously shown that a live-attenuated 
chimeric PCV1-2 vaccine prevented viremia and decreased macroscopic and microscopic 
lesions caused by PCV2 infection (12). Interestingly, recently a chimeric PCV1-2 was 
recovered from clinically healthy pigs on Canadian farms with no signs of PCVAD (17). 
Another concern with a live-attenuated chimeric vaccine based on the PCV1 backbone is the 
disease causing potential of PCV1. It has been previously shown that PCV1 is associated 
with congenital tremors in newborn fetuses (Hines, RK and Lukert, PD, 1994: Porcine 
circovirus as a cause of congenital tremors in newborn pigs. Proc Am Assoc Swine Pract. 
Chicago, IL. 25:344-345), but other authors failed to reproduce these initial findings (18,19). 
Recently, PCV1 has been associated with hemorrhages in lung tissues of fetuses 
experimentally inoculated with the PK-15 cell-derived PCV1 isolate but not a field isolate of 
PCV1 (20).   
PCV2 is known to be shed in oral, nasal, and fecal excretions (21,22,23), and has 
recently been shown to be shed in boar semen without damaging sperm morphology (24). It 
has also been shown that insemination of naïve dams with semen containing low levels of 
PCV2 DNA did not result in virus transmission (viremia, seroconversion) or reproductive 
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failure (25); however, insemination with semen spiked with high levels of PCV2 was capable 
of inducing reproductive failure in naïve dams (10).  
The objective of this study was to determine efficacy of a commercial inactivated 
(administered as one or two dose) vaccine and an experimental live-attenuated chimeric 
PCV1-2 vaccine to prevent viremia in sows using the PCV2-spiked semen model. Four of the 
35 sows became pregnant including two vaccinated sows (two dose inactivated and one dose 
live-attenuated PCV1-2 vaccine), a negative control and a positive control sow, and their 
litters were utilized to further determine the efficacy of sow vaccination in preventing or 
reducing vertical transmission. 
 
Materials and Methods 
Animals and housing 
Thirty-five dams, ranging in age from 792 to 2,389 days (Table 1), were obtained 
from a herd confirmed to be free of PCV2 by serology and PCR testing. The dams were 
transported over a three day interval approximately 250 km to Iowa State University in 
Ames, Iowa and housed in groups of 1 to 6 depending on room size. Each room was 
equipped with one nipple drinker and sows were fed daily with a pelleted feed ration which 
contained whey but was free of other animal proteins and antibiotics (Nature’s Made, 
Heartland Co-op, Cambridge, IA). Fifteen of the 35 dams were pregnant on arrival (between 
15-116 days of gestation) and the pregnancies were terminated in all dams less than 52 days 
into gestation by using 2 ml cloprostenol sodium (Estrumate®, Intervet/Schering-Plough 
Animal Health). The dams were also given 3 ml ceftiofur (Excede® Pfizer Animal Health).  
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Experimental design 
The experimental protocol was approved by the Iowa State University Institutional 
Animal Care and Use Committee. The experimental design is summarized in Table I. After 
arrival, the dams were blocked by age and randomly assigned to groups and rooms. After an 
acclimation period of approximately 3 months, 12/35 dams were vaccinated with one 2 ml 
dose of an experimental live-attenuated chimeric PCV1-2 vaccine (1-LIVE-VAC, and 1-
LIVE-VAC-PCV2), 6/35 dams were vaccinated with one 2 ml dose of an inactivated 
chimeric PCV1-2 vaccine (1-VAC-PCV2), 6/35 dams were vaccinated with two 1 ml doses 
of an inactivated chimeric PCV1-2 vaccine three weeks apart (2-VAC-PCV2), and 11/35 
dams remained unvaccinated as controls. Estrus cycles were synchronized for all dams as 
previously described (10) followed by artificial insemination 35 days post one dose 
inactivated chimeric or live vaccination or 14 days post two dose inactivated chimeric 
vaccination. Extended semen obtained from 9 boars all of the same breed and confirmed to 
be PCV2 negative was used for artificial insemination. Each dam in the negative control 
group and in the 1-LIVE-VAC group received 80 ml of PCV2 free semen. All dams in the 
other groups were inseminated with 75 ml of semen spiked with 5 ml of PCV2b immediately 
before insemination. Inseminations were repeated in 24 h intervals for 3 days. Dams were 
monitored for signs of estrus, and if any recycled they were re-inseminated using 80 ml 
PCV2 free semen in 24 h intervals for 3 days. After vaccination, the dams were bled weekly 
until necropsy at 105 days post inoculation (DPI). All dams tested negative for specific 
antibodies against porcine respiratory and reproductive syndrome virus and porcine 
parvovirus prior to initiation of the study and at termination of the study (data not shown). At 
necropsy all fetuses were removed from the uterus, euthanized, and samples were collected. 
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Vaccination 
Dams in the 1-VAC-PCV2 group were vaccinated with 2 ml of Suvaxyn® PCV2 
(Fort Dodge Animal Health Inc.; now reformulated and known as “FosteraTM PCV” from 
Pfizer Animal Health Inc.), dams in the 2-VAC-PCV2 group were vaccinated with two 1 ml 
doses of Suvaxyn® PCV2 three weeks apart, and dams in the 1-LIVE-VAC and 1-LIVE-
VAC-PCV2 groups were vaccinated with one 2 ml dose of an experimental live-attenuated 
chimeric PCV1-2 vaccine at a dose of 104 median tissue culture infective dose (TCID50) as 
described (29). 
 
Clinical observation 
All dams were examined daily for signs of illness such as lethargy, respiratory 
disease, inappetence, and lameness as well as signs of return to estrus. 
 
Inoculation 
The PCV2b isolate NC-16845 (16) used for the inoculation was propagated in PCV1-
free PK-15 cells  to an infectious titer of 104.5 TCID50. Five weeks after arrival and 
vaccination, semen was spiked with 5 ml PCV2b and used to artificially inseminate 24/35 of 
the dams (1-VAC-PCV2; 2-VAC-PCV2, 1-LIVE-VAC-PCV2, positive controls).   
 
Sample collection 
Blood was collected from dams in 8.5 ml serum separator tubes (BD vacutainer®, 
BD Biosciences) on a weekly basis from the time of vaccination until necropsy at DPI 105 
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(except on DPI 63). At necropsy, fetal blood was collected from all live fetuses and fetal 
thoracic fluid was collected from all dead or mummified fetuses if possible. The blood was 
centrifuged at 3220 × g for 10 min at 4ºC and the serum was aliquoted into 5 ml polystyrene 
round bottom tubes (Fisher Scientific, Inc.) and stored at -20ºC until testing. 
 
Serology 
All serum samples were tested for PCV2-specific IgG antibodies using an indirect 
PCV2 ORF2-based ELISA as previously described (26). The results were expressed as 
sample-to-positive (S/P) ratio. Samples were considered to be negative if the S/P ratio was 
less than 0.2 and positive if the S/P ratio was greater than or equal to 0.2. In addition, all 
serum samples from dams at DPI 0 were tested for PCV2-specific neutralizing antibodies 
using a fluorescence focus neutralization (FFN) assay (27). Virus neutralizing titers are 
expressed as the highest serum dilution resulting in a 90% reduction in virus replication 
compared to the virus control.  
 
PCV2 viremia detection 
All serum samples or fetal thoracic fluid samples were tested for the presence and 
quantity of PCV2 DNA by a quantitative PCV2 PCR. If no serum or fetal thoracic fluid 
could be collected from a fetus, PCR was run on tissue homogenates. PCV2 viral DNA was 
extracted from the samples using the MagMaxTM Viral Isolation Kit (Applied Biosystems, 
Carlsbad, CA) on the KingFisher Flex System (ThermoFisher Scientific, Pittsburgh, PA). 
PCV2 DNA detection to verify and quantify the presence of PCV2 in all samples was done 
by a quantitative real-time PCR using the same primers and probe at the same concentrations 
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as previously described (28) using the TaqMan® Fast Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA). The total PCR reaction volume including 2.5 µl of DNA 
extract was 25 µl. The thermal cycle conditions were 95 °C for 2 min, followed by 40 cycles 
of 95 °C for 10 s and 60 °C for 1 min. Samples were considered negative if no signal was 
observed during the 40 amplification cycles. 
 
PCV1-2 PCR 
PCV1-2 DNA detection was done to verify the presence of any PCV1-2 using the 
same DNA extracts as for the PCV2 PCR. DNA quantification was done by quantitative real-
time PCR using the same primers and probes at the same concentrations as previously 
described (29) using the TaqMan® Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA). The total PCR reaction volume was 25 µl. The thermal cycle conditions were 
50ºC for 2 min, 95ºC for 10 min, followed by 40 cycles of 95ºC for 15 sec, 55ºC for 30 sec, 
and 60ºC for 1 min. The sensitivity of the PCV1-2a real-time PCR was 8.13×104 copies/ml 
(204 copies per reaction). Samples were considered negative if no signal was observed 
during the 40 amplification cycles. 
 
Necropsy 
All dams were humanely euthanized by intravenous pentobarbital sodium overdose 
(Fatal Plus ®, Vortech Pharmaceuticals, LTD, Dearborn, MI) and necropsied at DPI 105. 
The extent of total macroscopic lung lesions (ranging from 0% to 100%) was scored by a 
veterinary pathologist in a blinded fashion as previously described (30). Fetuses were 
surgically removed from the uterus immediately after euthanasia of the dam. Fetal blood was 
33 
 
collected from all live fetuses, and the piglets were then humanely euthanized by intravenous 
pentobarbital sodium overdose (Vortech Pharmaceuticals, LTD) and necropsied. If blood 
collection was not possible (mummified or dead fetuses), fetal thoracic fluid was collected if 
available. Fetal heart tissues were collected at necropsy, a section stored fresh at -20ºC until 
further testing and a section fixed in 10% neutral buffered formalin and then routinely 
processed for histological examination as previously described (10). 
 
Immunohistochemistry 
Immunohistochemistry (IHC) for detection of PCV2-specific antigen was performed 
on fetal hearts using a rabbit polyclonal antiserum (31). Antigen scoring was performed by a 
veterinary pathologist blinded to treatment groups and scores were reported from 0 (no 
antigen detected) to 3 (abundant PCV2 antigen) as previously described (32). 
 
Statistical analysis 
Statistical analysis of the data was performed using the SAS and JMP® softwares 
version 9.0.0 (SAS Institute, Cary, NC). Summary statistics were calculated for all groups to 
assess the overall quality of the data including normality. Real-time PCR results and FFN 
results were log10 transformed prior to statistical analysis. Continuous repeated measured 
data (PCV2 viremia, ELISA S/P ratios) were assessed with the repeated measures analysis of 
variance (ANOVA) method. In each repeated measures ANOVA analysis, group, time and 
their interaction were fixed effects whereas animal was the subject of repeated measures. 
Differences in response among groups were assessed using F-tests by time. Non-repeated 
measurements (FFN results) were assessed using one-way ANOVA. If an ANOVA F-test 
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was significant (p-value<0.05), then pairwise t-tests with the Tukey’s adjustment were used 
to assess specific group differences.   
 
Results 
Clinical observation 
One negative control dam and one 1-LIVE-VAC-PCV2 dam developed severe 
lameness and were euthanized at DPI 84. The overall conception rate of the sows was 11.4% 
(4/35 sows) after insemination during the first estrus cycle following synchronization and 
37.1% (13/35) after 16 sows were rebred during subsequent estrus cycles.   
 
Reproductive parameters 
Of the four sows that were pregnant after initial insemination using PCV2-spiked 
semen, the litter compositions were as follows: two mummies and 12 live fetuses (1-LIVE-
VAC-PCV2), four mummies and 11 live fetuses (2-VAC-PCV2), zero mummies and 10 live 
fetuses (negative control dam) and one mummy and 13 live fetuses (positive control dam). 
Fetuses that were not full term at necropsy (pregnant upon second insemination after 
returning to estrus) were excluded from analysis.  
 
Seroconversion to PCV2 
Negative control dams remained negative for PCV2-specific antibodies throughout 
the study (Figure I; Table II). All 1-VAC-PCV2 and 2-VAC-PCV2 dams had seroconverted 
to PCV2 prior to the first blood collection at DPI -7 (Table II). Five of six 1-LIVE-VAC and 
5/6 1-LIVE-VAC-PCV2 dams had seroconverted by DPI 7, respectively. There was a 
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significant group by time interaction (p<0.001). There was no significant difference in 
antibody levels between the 1-VAC-PCV2 and 2-VAC-PCV2 groups at any time points 
except at DPI -7 (Figure I). Also, there was no significant difference in antibody levels at any 
time points between the 1-LIVE-VAC and 1-LIVE-VAC-PCV2 groups (Figure I). Dams 
vaccinated with the inactivated vaccine had significantly higher (p<0.05) S/P ratios as 
detected by ELISA compared to those vaccinated with the live-attenuated vaccine at every 
DPI throughout the course of the study. Positive controls had similar S/P ratios as the LIVE-
VAC and 1-LIVE-VAC-PCV2 groups from DPI 28 through DPI 105 (Figure I). All 39 
fetuses from all four litters were negative for PCV2-specific antibodies at derivation (data not 
shown). 
 
Neutralizing antibodies 
At the day of challenge, the log10 transformed FFN titers were 2.71±0.08 for 1-VAC-
PCV2, 2.96±0.24 for 2-VAC-PCV2, 1.57±0.17 for 1-LIVE-VAC, 1.52±0.13 for 1-LIVE-
VAC-PCV2, 0.28±0.17 for the negative control group, and 0.28±0.18 for the positive control 
group. The inactivated chimeric PCV1-2 vaccine induced significantly higher (p<0.05) levels 
of neutralizing antibodies compared to the live-attenuated vaccine prior to challenge. 
 
PCV2 viremia 
Negative control dams as well as the 1-LIVE-VAC dams remained negative for 
PCV2 viremia throughout the study (Table III). There was a significant group by time 
interaction (p<0.001). Specifically, positive control dams developed PCV2 viremia by DPI 
14 and had significantly higher (p<0.05) levels of viremia from DPI 14 through DPI 56 when 
36 
 
compared to vaccinated groups (Figure II). Challenged, vaccinated dams had detectable 
PCV2 DNA at varying DPIs during the study (Table III) without significant differences 
among the vaccinated groups at any time point (Figure II). The prevalence and concentration 
of PCV2 DNA detected in the fetuses are summarized in Table IV. 
 
PCV1-2 viremia 
All dams remained negative for PCV1-2 DNA throughout the course of the study. 
Three of 14 fetuses from the 1-LIVE-VAC-PCV2 litter were positive for PCV1-2 DNA with 
an average log10 transformed mean amount PCV1-2 DNA of 6.45±0.31 per ml. All other 
piglets were negative for PCV1-2 DNA (data not shown). 
 
Macroscopic lesions 
Lungs, lymph nodes, and the reproductive tract of the dams were examined for gross 
lesions and all were macroscopically normal.  
 
Immunohistochemistry 
All 10 piglets from the negative control dam and all 29 piglets from the 2-VAC-
PCV2 and 1-LIVE-VAC-PCV2 dams were negative for PCV2 antigen in heart tissues. Low-
to-abundant amounts of PCV2 antigen were detected in 3 of 13 fetuses from the positive 
control dam. 
 
Discussion 
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Evidence from the field supports an association of PCV2 with reproductive failure. 
Although limited experimental trials have been conducted in breeding age animals, sows 
developed PCV2 viremia when inseminated with PCV2-positive semen (10). In the current 
study, sows were inseminated with PCV2 spiked semen and viremia was detected in the 
positive control group further confirming that PCV2 is infectious when administered via 
artificial insemination. Very limited evidence is available in the literature on the efficacy of 
use of inactivated PCV2 vaccines in breeding age animals indicating that PCV2-vaccinated 
dams still may deliver PCV2 positive piglets (33), potentially an important source of PCV2 
transmission in pig production systems.  
Currently there are three commercial vaccines on the market approved for use in 
healthy pigs (three weeks of age or older), and one vaccine is approved for use in both dams 
and growing pigs. All of these commercial vaccines are inactivated. Experimental and field 
trial evidence clearly demonstrates that use of these vaccines reduces losses associated with 
PCVAD in growing pigs (34,35). In the current study, for the first time an experimental 
attenuated live PCV1-2 vaccine was utilized in breeding age animals, and compared to two 
different dose regimens of the inactivated version of the vaccine. The results indicate that the 
use of the three different vaccination protocols all decreased PCV2 viremia and increased 
anti-PCV2-specific antibody production in dams when compared to the positive control 
group regardless of inactivation of the vaccine virus.  
The exact mechanism for the decrease of PCV2 viremia in vaccinated animals is 
unknown but likely due to development of a combination of cellular and humoral immune 
responses. Interestingly, the groups vaccinated with the inactivated chimeric PCV1-2 vaccine 
(1-VAC-PCV2 and 2-VAC-PCV2) developed detectable PCV2-specific antibody levels 
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earlier and maintained higher levels throughout the study compared to those vaccinated with 
the live-attenuated chimeric vaccine (1-LIVE-VAC and 1-LIVE-VAC-PCV2). In contrast to 
these results in breeding age animals, a previous study comparing several commercial and 
experimental vaccines in young pigs found no significant differences between any of the 
commercial vaccines (29).  
In Canada, PCV1-2 was recently isolated from three different pigs in three different 
herds vaccinated with a commercial PCV2 vaccine based on an inactivated chimeric PCV1-2 
(17). Several studies have shown that the PCV1-2 infectious DNA clones and the live-
attenuated PCV1-2 vaccine are capable of inducing an antibody response, but are attenuated 
in pigs and not capable of producing any characteristic lesions of PCV2 infection (11,12,36). 
In the current study, the 1-LIVE-VAC dams had no evidence of PCV2 or PCV1-2 viremia; 
however, they did develop a PCV2-specific antibody response. The 1-LIVE-VAC-PCV2 
dams developed PCV2 viremia at selected time points at low levels which quickly resolved. 
Overall, the results are similar to previous studies where some PCV1-2 vaccinated animals 
developed viremia while others did not; however, as in this study, the majority of the animals 
seroconverted and had no or minimal lesions characteristic of PCV2 infection (12,36). These 
results further confirm that the live PCV1-2 chimeric vaccine is capable of inducing a 
humeral immune response and remains attenuated.  
In this study, only 11.4% (4/35) of the sows became pregnant during the first artificial 
insemination and only 37.1% (13/35) sows became pregnant overall. Low reproductive rates 
are not uncommon in older parity sows. In addition, PCV2 has been implicated in early 
embryonic death (37) and re-absorption leading to irregular or regular return to estrus. 
Several sows arrived at the research facility with varying stages of pregnancy which were 
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purposely terminated, potentially causing complications in their ability to conceive during the 
subsequent artificial insemination attempts. However, previously, using the same 
insemination technique and PCV2 dose, conception rates of 88.9% (8/9) (38) and 66.7% 
(6/9) (10) were observed.  
Among the pregnant animals, PCV2-positive piglets were detected in all three 
challenged sows regardless of vaccination status further confirming that dam vaccination 
does not prevent vertical PCV2 transmission. The fact that sows can still deliver PCV2-
positive piglets causes some to question the value of vaccination in breeding age females; 
however, while the vaccines did not entirely prevent PCV2 spread to fetuses in the current 
study, vaccination did decrease the overall PCV2 load in the dam and fetuses.  
The vaccination protocols in the pregnant sows (1-LIVE-VAC-PCV2 and 2-VAC-
PCV2) resulted in a decrease in PCV2 DNA detection in piglets (28.6% and 66.7%, 
respectively) when compared to the positive control group (100%) indicating both types of 
the PCV1-2 chimeric vaccine are efficacious in breeding age animals. However, due to the 
low numbers of pregnancies in this study, these results should be interpreted with caution. In 
fetuses, PCV2antigen detection was performed on fetal heart tissues since it was previously 
shown that PCV2 antigen in fetuses was found predominantly in the heart and tonsil of 
piglets (33,38). PCV2 antigen was only detected in the positive control piglets in the current 
study. This is further confirmation that both vaccines are efficacious in decreasing levels of 
PCV2. 
To further evaluate the safety of the live-attenuated PCV1-2 vaccine, all fetuses were 
tested for presence of PCV1-2 DNA. Four of 14 piglets from the 1-LIVE-VAC-PCV2 dam 
were positive for PCV1-2 DNA at birth; however, no lesions were noted and no PCV2 
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antigen was detected in the fetal myocardium. As only fetal heart tissues were investigated in 
the current study, the tissue tropism of PCV1-2 is unknown, and PCV1 has been previously 
identified in fetal lung tissues (20), PCV1-2, although unlikely, could have been present 
elsewhere in the fetal tissues. As a PCV1-2 chimeric virus was identified in Canadian swine 
herds, the risks of introduction of a live-attenuated PCV2 vaccine for use in breeding age 
females needs to be seriously considered before approval. 
 
Conclusion 
To our knowledge this is the first study investigating the use of a live PCV2 vaccine 
in breeding animals. While the inactivated chimeric PCV1-2 vaccine was capable of inducing 
higher levels of PCV2-specific antibodies throughout the course of this study when compared 
to the live-attenuated experimental chimeric vaccine, no significant differences among 
vaccinated groups in levels and duration of PCV2 viremia were found. All vaccines were 
capable of reducing viremia in dams and despite some cross-placental transmission of PCV2, 
the piglets obtained from the two vaccinated dams had lower levels of PCV2 in comparison 
to those obtained from the non-vaccinated dam. Live-vaccine virus viremia was detected in 
selected dams and piglets at low levels which was not associated with myocardial lesions or 
antigen suggesting that the vaccine may be safe and effective for broader use in breeding 
herds. 
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Table I 
Experimental design. 
Group Animals Mean age in days PCV2 Vaccine PCV2 
inoculation 
(95% CI) 35* 14* 
Negative Control 5 1,048 (1,290; 806) - - - 
Positive Control 6 1,174 (1,421; 928) - - Spiked 
semen 
2-VAC-PCV2a 6 1,247 (1,654; 841) YES YES Spiked 
semen 
1-VAC-PCV2a 6 1,291 (1,836; 746) YES - Spiked 
semen 
1-LIVE-VAC-PCV2b 6 1,462 (1,991; 935) YES - Spiked 
semen 
1-LIVE-VACb 6 1,363 (1,719; 1,008) YES - - 
aDams vaccinated with Suvaxyn® PCV. 
bDams vaccinated with an experimental live-attenuated chimeric PCV1-2 vaccine.
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Table II 
Group prevalence of PCV2-specific antibodies in serum. Groups that contain seropositive 
pigs are shaded in grey. Vaccines were administered at -35 days post inoculation and in the 
case of the 2 dose product a second dose was given at -14 days post inoculation. Dams were 
challenged at 0 days post inoculation with PCV2 free or PCV2 spiked semen. 
Group 
Days post inoculation 
-7 0 7 14 21 28 35 42 49 56 77 84 91 98 105 
1-VAC-
PCV2 
6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 
2-VAC-
PCV2 
6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 
1-LIVE-
VAC 
1/6 3/6 5/6 5/6 5/6 5/6 5/6 5/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 
1-LIVE-
VAC-
PCV2 
2/6 4/6 5/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 5/5a 5/5a 5/5a 
Negative 
controls 
0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/4a 0/4a 0/4a 
Positive 
controls 
0/6 0/6 0/6 0/6 0/6 4/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 
aOne negative control dam and a 1-LIVE-VAC-PCV2 dam developed severe lameness and 
were euthanized at DPI 84. 
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Table III 
Group prevalence of PCV2 DNA in serum. Groups that contain viremic pigs are shaded in 
grey. Vaccines were administered at -35 days post inoculation and in the case of the two dose 
product a second dose was given at -14 days post inoculation. Dams were challenged at 0 
days post inoculation with PCV2 free or PCV2 spiked semen. 
Group 
Days post inoculation 
0 7 14 21 28 35 42 49 56 77 84 91 98 105 
1-VAC-PCV2 0/6 0/6 0/6 1/6 0/6 1/6 0/6 1/6 0/6 0/6 0/6 1/6 0/6 0/6 
2-VAC-PCV2 0/6 0/6 0/6 1/6 0/6 0/6 0/6 1/6 0/6 1/6 0/6 0/6 1/6 0/6 
1-LIVE-VAC 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 
1-LIVE-VAC-
PCV2 
0/6 0/6 1/6 1/6 1/6 0/6 0/6 0/6 0/6 0/6 0/6 0/5a 0/5a 0/5a 
Negative controls 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/4a 0/4a 0/4a 
Positive controls 0/6 0/6 6/6 6/6 6/6 6/6 5/6 5/6 4/6 3/6 1/6 1/6 3/6 3/6 
aOne negative control dam and a 1-LIVE-VAC-PCV2 dam developed severe lameness and 
were euthanized at DPI 84. 
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Table IV 
Mean group amount of log10 PCV2 DNA and prevalence in serum or fetal thoracic fluid of 
piglets born to dams vaccinated or unvaccinated and infected with PCV2. A sample with no 
threshold cycle (CT) value during the 40 amplification cycles was considered negative.  
Treatment PCV2 DNA Prevalence 
2-VAC-PCV2 3.09±0.67 10/15 
1-LIVE-VAC-PCV2 1.65±0.74 4/14 
Negative Control 0.00±0.00 0/10 
Positive Control 6.72±0.57 13/13 
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Figure I 
Mean group PCV2 ELISA sample-to-positive (S/P) ratios in serum at different days post 
inoculation. An S/P ratio equal or greater than 0.2 was considered positive. Groups with 
different letters (A,B,C) on a certain day post inoculation have significantly (p<0.05) 
different group S/P ratios.  
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Figure II 
Mean group amount of log10 PCV2 DNA in serum at different days post inoculation. A 
sample with no threshold cycle (CT) value during the 40 amplification cycles was considered 
negative. Asterisks indicate a significant (p<0.05) difference between positive controls and 
all other PCV2 challenged groups (1-LIVE-VAC-PCV2, 1-VAC-PCV2, 2-VAC-PCV2) on 
that day post inoculation. 
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CHAPTER 4: VACCINATION WITH INACTIVATED OR LIVE-
ATTENUATED CHIMERIC PCV1-2 RESULTS IN DECREASED 
VIREMIA IN CHALLENGE-EXPOSED PIGS AND MAY REDUCE 
TRANSMISSION OF PCV2 
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Abstract 
The objectives were to determine transmissibility of PCV2 to naïve contact pigs 140 
days after infection of resident pigs and the benefit of vaccination with live-attenuated or 
inactivated chimeric PCV2 vaccines on chronic PCV2 infection. Twelve 6-week old PCV2 
naïve pigs were randomly divided into four groups of three pigs: negative controls, positive 
controls, and pigs vaccinated with either a live-attenuated or inactivated chimeric PCV1–2 
vaccine. All animals were bled weekly and tested for anti-PCV2 antibodies and PCV2 and 
PCV1–2 DNA and all groups except negative controls were challenged at 10 weeks. Two 
pigs vaccinated with the live PCV2 vaccine were PCV1–2 viremic at a single observation 
point. Both vaccine regimens induced an anti-PCV2 antibody response which was detected 
sooner and reached a higher level with the commercial inactivated vaccine. Both vaccines 
significantly decreased the concentration and duration of PCV2 viremia compared to the 
positive controls. PCV2 DNA was detected in lymphoid tissues of 1/3 pigs in the live-
attenuated vaccine group and 3/3 positive control pigs. Three, 2-week old, PCV2 naïve 
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contact pigs were comingled with each group at 168 days post-vaccination or 140 days post-
challenge. After seven days of co-housing, the resident pigs were removed and the contact 
pigs remained for six weeks. Evidence of chimeric PCV1–2 vaccine or PCV2 challenge virus 
transmission to naïve contact pigs was lacking in all groups. The results of this study suggest 
that 140-day closure of a small pig population in a controlled environment may result in 
stabilization and elimination of PCV2. 
Keywords: Porcine circovirus type 2, vaccination, transmission 
 
1. Introduction 
Porcine circovirus type 2 (PCV2) is a ubiquitous virus found in most pork producing 
regions (Patterson and Opriessnig, 2010) and has been identified as the main cause of a series 
of diseases collectively called porcine circovirus associated disease (PCVAD). PCVAD has 
been implicated in high production losses and most commonly manifests as post-weaning 
multisystemic wasting syndrome, reproductive failure, enteritis, or respiratory disease 
(Opriessnig et al., 2007; Gillespie et al., 2009). 
In order to understand and control PCVAD, knowledge of the transmission of PCV2 
and proper disinfection protocols are important. A substantial amount of work has been done 
testing the efficacy of cleaning and disinfection protocols for PCV2 in research facilities and 
transportation vehicles (Martín et al., 2008; Patterson et al., 2011a) and PCV2 was found to 
be stable in the environment and resistant to most disinfectants (Patterson and Opriessnig, 
2010). Moreover, PCV2 can be detected for extend periods of time in serum and tissues of 
pigs after experimental infections (Opriessnig et al., 2010b; Patterson et al., 2011b). The 
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often long duration of PCV2 viremia in certain pigs raises questions and concerns about the 
related risk of PCV2 transmission to PCV2 negative cohorts. 
Several commercial PCV2 vaccines have been developed to reduce or prevent 
PCVAD in pigs. Two of these vaccines are subunit vaccines based on PCV2 capsid protein 
expressed in baculovirus, one is an inactivated PCV2 vaccine, and one is an inactivated 
chimeric PCV1–2 vaccine. The chimeric PCV1–2 vaccine is produced with the ORF2 capsid 
gene of the PCV2a cloned into the genomic backbone of the non-pathogenic PCV1 (Fenaux 
et al., 2003, 2004). A reformulated version of the chimeric PCV1–2 vaccine (Suvaxyn® 
PCV, Fort Dodge Animal Health Inc.) re-entered the market in August 2011 under a new 
brand name (FosteraTM PCV, Pfizer Animal Health Inc.). 
The objectives of this study were (1) to determine the ability of PCV2 to be 
transmitted to naïve pigs 140 days after infection of the resident animals and (2) to determine 
if vaccination with a commercial inactivated PCV1–2 vaccine or an experimental live-
attenuated PCV1–2 vaccine is safe and beneficial in this scenario. 
 
2. Materials and methods 
2.1. Pig source and arrival 
Twelve, 6-week-old, pigs (‘‘residents’’) were obtained from a herd confirmed to be 
free of PCV2 and porcine reproductive and respiratory syndrome virus (PRRSV) as 
determined by routine serology. Twelve 2-week-old pigs (‘‘contacts’’) from the same herd as 
the first group of pigs were weaned and transported to the isolation facility to serve as contact 
pigs. The pigs were transported 168 days apart (Fig. 1) to a Biosafety Level 2 (BSL-2) 
animal facility at Iowa State University, Ames, IA. 
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2.2. Animals housing 
The resident pigs were randomly assigned to one of three groups and were kept in 
four separate 2 m x 2.5 m rooms. Each room had one pen and was equipped with one nipple 
drinker and pigs were fed daily with a pelleted feed ration that contained whey but was free 
of other animal proteins and antibiotics (Nature’s Made; Heartland Co-op; Cambridge, IA). 
On day R154 (=154 days after the resident pigs were vaccinated), the resident pigs were 
moved into larger rooms which contained two pens separated by a gate with vertical bars that 
allowed for nose-to-nose contact. The resident pigs were kept in one of the two pens. On day 
R168, three contact pigs were placed in a separate pen (=arrival of contact pigs or C0) with 
nose-to-nose contact with the resident pigs. 
 
2.3. Experimental design 
The experimental protocol was approved by the Iowa State University Institutional 
Animal Care and Use Committee and the timeline for the experiment is summarized in Fig. 
1. Six-week-old PCV2 naïve resident pigs were either vaccinated with an experimental live-
attenuated PCV1–2 vaccine (n = 3), vaccinated with a commercial inactivated PCV1–2 
vaccine (n = 3), or remained unvaccinated (n = 6). A sample size of three was chosen as it is 
the smallest number considered reasonable for statistical analysis and because the limited 
availability of PCV2-free pigs and funding prevented the use of larger group sizes. On day 
R28, when the resident pigs were 10 weeks old, 9 of the 12 pigs were inoculated intranasally 
(2 ml) and intramuscularly (1 ml) with PCV2b. All pigs were bled once a week until 
necropsy and the serum samples were tested for the presence of PCV2 DNA, chimeric 
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PCV1–2 vaccine virus DNA and anti-PCV2 antibodies. At day R168 (=140 days post 
challenge) or C0, three PCV2 naïve contact pigs were moved into each room. Similarly to the 
resident pigs, blood was collected from the contact pigs weekly. Necropsy was conducted on 
day R175 for the 12 resident pigs and on day C49 for the 12 contact pigs. Macroscopic and 
microscopic lesions were compared between groups and lymphoid tissues were assessed for 
presence of PCV2 antigen and DNA. 
 
2.4. Clinical observations, vaccination, inoculation, and sample collections 
All pigs were examined daily for signs of clinical disease such as lethargy, respiratory 
disease, inappetence and lameness. On day R0, resident pigs in the inactivated vaccine group 
were vaccinated with 2 ml of Suvaxyn® PCV (now reformulated and known as ‘‘FosteraTM 
PCV’’ from Pfizer Animal Health Inc.) based on a chimeric PCV1–2a. The resident pigs in 
the live-attenuated vaccine group were vaccinated with 2 ml of an experimental live-
attenuated PCV2 vaccine based on a chimeric PCV1–2b (Beach et al., 2010) that has been 
shown to decrease viremia, microscopic lesions, and PCV2 antigen (Opriessnig et al., 2011). 
Vaccination was done by intramuscular injection into the right neck area. On day R28, 
vaccinated and positive control pigs were challenged with 2 ml (intra-nasally) and 1 ml 
(intramuscularly) of a PCV2b virus stock inoculum. The PCV2 isolate NC-16845 
(Opriessnig et al., 2008) used for the challenge was based on an infectious clone as described 
(Opriessnig et al., 2008) and further propagated in PK-15 cells to an infectious titer of 104.5 
50% tissue culture infective dose (TCID50) per ml. The weekly collected blood samples from 
resident and contact were centrifuged at 3220 x g for 10 min at 4°C, and the serum was 
aliquoted into 5 ml polystyrene round bottom tubes and stored at -20°C until testing. Lymph 
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node samples (tracheobronchial lymph nodes, mesenteric lymph nodes, mediastinal lymph 
nodes, superficial inguinal lymph nodes) were collected from each pig at necropsy and stored 
at -80°C until testing. 
 
2.5. Laboratory methods used 
2.5.1. Serology 
All serum samples were tested for anti-PCV2 antibodies using an indirect PCV2-
ORF2-based ELISA as previously described (Nawagitgul et al., 2002). The results were 
expressed as sample-to-positive (S/P) ratio. Samples were considered to be negative if the 
S/P ratio was less than 0.2, and positive if the S/P ratio was greater than or equal to 0.2. In 
addition, all serum samples from resident pigs obtained on day R28 (day of PCV2 challenge) 
were tested for PCV2- specific neutralizing antibodies using a fluorescence focus 
neutralization (FFN) assay (Pogranichniy et al., 2000). Virus neutralizing titers were 
expressed as the highest serum dilution in which 50% of virus is neutralized compared to the 
control virus. 
 
2.5.2. PCV2 and PCV1–2 DNA detection 
All serum samples and pooled lymph nodes were tested for the presence and quantity 
of PCV2 DNA by a quantitative real-time PCR (Opriessnig et al., 2003). Total DNA was 
extracted from serum samples using the MagMaxTM Viral Isolation Kit (Applied Biosystems, 
Life Technologies, Carlsbad, CA) on the KingFisher Flex System (ThermoFisher Scientific, 
Pittsburgh, PA). Total DNA was extracted from lymph node homogenates using the 
QIAamp® DNA Mini Kit (Qiagen, Valencia, CA). In addition, the sera and lymphoid tissues 
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were also tested for chimeric PCV1–2 vaccine virus DNA by real-time PCR as described 
(Shen et al., 2010). A sample was considered negative if no threshold cycle (CT) was 
detected in 40 amplification cycles. 
 
2.6. Post mortem examination 
2.6.1. Necropsy 
All pigs were humanely euthanized by intravenous pentobarbital sodium overdose 
(Fatal Plus®, Vortech Pharmaceuticals, Ltd., Dearborn, MI) and necropsied at day R175 (31 
weeks of age, resident pigs) or at day C49 (9 weeks of age, contact pigs), respectively. The 
total extent of macroscopic lung lesions (ranging from 0% to 100%) was scored subjectively 
by a veterinary pathologist (TO) as previously described (Halbur et al., 1995). Lymph nodes 
were scored from 0 (normal) to 4 (enlarged, 3 times normal size) (Opriessnig et al., 2004). 
Sections of tracheobronchial lymph nodes, mesenteric lymph nodes, mediastinal lymph 
nodes, superficial inguinal lymph nodes, tonsil, thymus, spleen, kidney, liver, heart, small 
intestine, colon and lungs were collected at necropsy and fixed in 10% neutral buffered 
formalin. Tissues were then routinely processed for histological examination, embedded in 
paraffin and stained with hematoxylin and eosin. Sections of all lymph nodes were also 
collected in separate bags for PCR analysis as described under Section 2.4. 
 
2.6.2. Histopathology 
Microscopic lesions were examined and scored by a veterinary pathologist (TO) 
blinded to the treatment groups as described (Opriessnig et al., 2004). Briefly, lung tissues 
were scored for the severity of interstitial pneumonia ranging from 0 (normal) to 6 (severe 
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diffuse). Sections of thymus, kidney, liver, heart, small intestine, and colon were scored for 
the severity of lymphohistiocytic inflammation ranging from 0 (none) to 3 (severe). Sections 
of lymphoid tissues (lymph nodes, tonsil and spleen) were scored for lymphoid depletion 
ranging from 0 (none) to 3 (severe) and for lymphohistiocytic inflammation and replacement 
of follicles ranging from 0 (none) to 3 (severe). 
 
2.6.3. Immunohistochemistry 
Immunohistochemical detection of PCV2-specific antigen was performed on selected 
formalin-fixed sections of lymphoid tissues using a rabbit polyclonal antiserum (Sorden et 
al., 1999). Antigen scoring was performed by a veterinary pathologist (TO) blinded to 
treatment groups and scores were reported from 0 (no antigen detected) to 3 (more than 50% 
of cells contained PCV2 antigen) as previously described (Opriessnig et al., 2004). 
 
2.7. Statistical analysis 
Statistical analysis of the data was performed using the JMP® software version 9.0.0 
(SAS Institute, Cary, NC). Summary statistics were calculated for all groups to assess the 
overall quality of the data including normality. One-way analysis of variance (ANOVA) was 
used to evaluate the differences among treatment groups. If differences in group means were 
observed then Tukey–Kramer test was used for each pair-wise comparison. A P-value of less 
than 0.05 was set as a statistically significant level throughout this study. Real-time PCR 
results (PCV2 DNA copies per ml of serum) and FFN titers were log10 transformed prior to 
statistical analysis. All group means were calculated using results from all animals in each 
group with negative results reported as 0 for the statistical analysis. 
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3. Results 
3.1. Clinical observations 
One positive control pig developed lameness 63 days after PCV2 challenge, was 
treated with 1 ml ceftiofur (Excede®, Pfizer Inc., New York City, NY) and subsequently 
recovered. All other animals remained clinically healthy. 
 
3.2. Seroconversion to PCV2 and neutralizing antibodies 
3.2.1. Anti PCV2-IgG 
All resident negative controls (Fig. 2) and all contact pigs remained seronegative for 
PCV2 for the duration of the study. All animals vaccinated with the inactivated PCV2 
vaccine seroconverted to PCV2 by day R21 and remained seropositive for the remainder of 
the study. All animals vaccinated with the live-attenuated PCV2 vaccine seroconverted 
between days R28 and R42 and remained seropositive for the remainder of the study. All 
positive control pigs seroconverted to PCV2 by day R49 (which corresponds to 21 days after 
PCV2 challenge) and remained seropositive for the remainder of the study. In addition to 
earlier seroconversion, the pigs vaccinated with the inactivated PCV2 vaccine had 
significantly (P < 0.05) higher mean group anti-PCV2 IgG S/P ratios than those vaccinated 
with the live-attenuated PCV2 vaccine from day R21 through R49 (Fig. 2). 
 
3.2.2. Neutralizing antibodies 
The pigs vaccinated with the inactivated PCV2 vaccine had significantly (P < 0.05) 
higher concentrations of neutralizing antibodies at day R21 than pigs vaccinated with the 
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live-attenuated PCV2 vaccine (2.71 ± 0.00 versus 1.61 ± 0.26) at which time positive and 
negative control pigs had no detectable anti-PCV2 neutralizing antibodies. 
 
3.3. PCV2 and PCV1–2 DNA detection in sera and lymphoid tissues 
3.3.1. PCV2 
All resident negative controls and all contact pigs remained negative for PCV2 DNA 
for the duration of the study (data not shown). Positive control animals became PCV2 
viremic at day R35 (7 days post PCV2 challenge) and remained viremic until day R147 (119 
days post PCV2 challenge) and had significantly (P < 0.05) higher concentration of DNA 
from PCV2 in serum compared to all other groups (Fig. 3). The group mean amount of log10 
PCV2 DNA was significantly (P < 0.05) lower for both vaccinated groups compared to the 
positive control group on days R42, R63, R70, R77 and R84. In both vaccinated groups, 
PCV2 DNA was detected sporadically throughout the study (Fig. 3). At necropsy, PCV2 
DNA in lymphoid tissues was detected in 3/3 positive controls and 1/3 pigs in the live-
attenuated vaccine group. PCV2 DNA was not detected in any of the lymphoid tissues of the 
other resident or contact pigs (data not shown). 
 
3.3.2. PCV1–2 
Two of three animals vaccinated with the live-attenuated PCV2 vaccine were positive 
for PCV1–2 DNA in serum on days R21 and R28 after vaccination, respectively. All other 
animals (residents and contacts) were negative for PCV1–2 DNA at all time points tested. 
PCV1–2 DNA was not detected in any of the lymphoid tissues. 
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3.4. Macroscopic and microscopic lesions and amount of PCV2 antigen 
No macroscopic lesions were noted on any animals at necropsy. No microscopic 
lesions were observed in the lymphoid tissues of pigs (residents and contacts) in any of the 
treatment groups. Low amounts of PCV2 antigen (score 1) were detected in lymphoid tissues 
and tonsil of two of three resident positive control pigs. In addition, individual resident pigs 
from all treatment groups had mild interstitial pneumonia (score 1) characterized by 
increased numbers of lymphocytes and macrophages in alveolar septa. 
 
4. Discussion 
The current study demonstrated that a small closed group of growing pigs exposed to 
PCV2 140 days earlier did not transmit PCV2 to naïve contact pigs suggesting that under the 
conditions of the study, closure of the population to new animal entries for 140 days may 
stabilize population immunity resulting in elimination of infectious PCV2. It should be noted 
that the risk of re-exposure from the environment (PCV2 present in the rooms) was 
minimized in the current study by moving the population into disinfected rooms at 128 days 
post challenge. This work needs to be repeated under field conditions to increase sample size 
and better simulate population infection dynamics where not all pigs in the population are 
infected on the same day and co-infections are common. 
Several studies have shown that acutely infected pigs can transmit PCV2 to naïve 
contact animals (Bolin et al., 2001; Patterson et al., 2011b), but to the authors’ knowledge the 
transmissibility of PCV2 from long-term infected pigs to naïve animals has not been 
examined to date. In our earlier study in growing pigs, four of six animals inoculated with 
PCV2a were positive for PCV2 DNA at 140 days after challenge; however, viremia was 
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intermittent from 63 to 140 days post challenge (Opriessnig et al., 2010b). Similar results 
were seen in the current study where PCV2 viremia in unvaccinated, PCV2 challenged pigs 
was intermittent between 77 and 119 days after infection; however, no evidence of viremia 
was detected after day 119 post challenge. One difference that could account for the 
discrepancy in length of detection of viremia between studies (140 days versus 119 days post 
challenge) is that different DNA extraction methods were used in the two studies with 
potential differences in sensitivity. Another possibility for the overall shorter viremia length 
in the positive control pigs in the current study could be the use of different PCV2 challenge 
isolates. In the previous study a PCV2a isolate was used for challenge (Opriessnig et al., 
2010b) while a PCV2b isolate was used in this current study. Additionally, due to limited 
availability of PCV2 free pigs of different ages, 2-week-old contact pigs were used and were 
brought in nose-to-nose contact with the older resident pigs. The age difference could be 
important for overall contact time and could have affected the infection rate in this study. 
Interestingly, in the current study, PCV2 DNA was detected in lymphoid tissues of all 
positive controls but only in one of six vaccinated pigs (attenuated-live vaccine group) at the 
time of necropsy perhaps indicating that vaccination could reduce chronic infection. Most 
published experiments investigating PCV2 vaccine efficacy have been terminated 21 days 
after infection with PCV2 (Fenaux et al., 2004; Fort et al., 2009; Shen et al., 2010; 
Opriessnig et al., 2010a, 2011; Xujie et al., 2011). One of the goals of this study was to 
determine the efficacy of an inactivated and a live-attenuated PCV1–2 vaccine in reducing 
viremia and lesions in pigs over a longer period of time. Similar to previous experiments, 
both vaccines substantially reduced detectable PCV2 viremia. Interestingly, all animals 
vaccinated with the inactivated PCV2 vaccine developed higher concentrations of anti-PCV2 
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IgG more quickly post-vaccination than those vaccinated with the live-attenuated vaccine, 
whereas in a previous study no significant differences in mean group anti-PCV2 S/P ratios 
were observed between the two vaccinated groups (Shen et al., 2010). After day 49 (21 days 
post PCV2 challenge), both vaccinated groups in this study continued to have intermittent, 
sporadic viremia; however, all vaccinated pigs were negative for PCV2 DNA after day 126. 
In the current study, PCV1–2 vaccine viremia was not detected in any of the pigs 
vaccinated with the inactivated commercial vaccine. However, we did detect a low 
concentration of PCV1–2 DNA at days R21 and R28 in two of three animals after 
vaccination with the live-attenuated PCV2 vaccine which is consistent with previous reports 
(Opriessnig et al., 2011). PCV1–2 vaccine viremia was not detected in any contact pigs 
throughout the study indicating that vaccine virus was not transmissible 168 days after 
vaccination. 
PCV2-associated microscopic lesions were not observed in this study, and this was 
not unexpected since PCV2-associated lesions typically develop around 21 days after PCV2 
infection in experimentally infected pigs and begin to resolve approximately two weeks later 
(Opriessnig et al., 2010b). Since the time of necropsy in this study was at 147 days after 
PCV2 infection, as expected, only minimal lesions were observed and no significant 
differences were found between groups. Fecal and nasal viral excretion of PCV2 were not 
measured in this study, but could prove useful in a future study. Although the results from 
this pilot study are encouraging for application of herd closure, which is essentially closure 
of the population to new animal entries, to reduce PCV2 transmission and PCVAD, more 
work needs to be conducted using larger numbers of pigs under field conditions to verify the 
data from this pilot study. 
64 
 
 
5. Conclusions 
Under the study conditions, PCV2 virus was not transmitted to naïve pigs that had 
nose-to-nose contact with pigs that had been challenged 140 days earlier implying that 
closure of a pig population may result in stabilization and elimination of PCV2. The 
attenuated and live vaccines performed similar in reducing the duration and concentration of 
PCV2 viremia in vaccinated pigs. In addition, live PCV2 vaccine virus was not transmitted to 
naïve pigs with nose-to-nose contact to vaccinated pigs 168 days after vaccination. 
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Fig. 1. Experimental design indicating the timeline in days for each event for resident pigs 
(indicated by an “R”) and contact pigs (indicated by a “C”). 
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Fig. 2. Mean group amount of anti-PCV2 IgG (± SEM) in serum of resident pigs vaccinated 
with an inactivated or a live PCV1–2 vaccine and in positive and negative control 
groups. The results are expressed as ELISA sample to positive (S/P) ratio. A sample 
was considered negative if the S/P ratio was less than 0.20. *Indicates significantly (P 
< 0.05) different group mean S/P ratios between the two vaccinated groups. 
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Fig. 3. PCV2 DNA concentration presented as mean group log10 PCV2 DNA (± SEM) in 
serum samples and prevalence of PCV2 DNA positive resident pigs vaccinated with 
an inactivated or a live PCV1–2 vaccine and in positive control animals after PCV2 
challenge at day 28. The prevalence was combined for the two vaccinated groups. A 
sample was considered to be negative if the no signal was detected in the 40 cycles. 
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CHAPTER 5: GENERAL CONCLUSIONS 
 
Porcine circovirus (PCV) type 2 (PCV2) has been associated with a series of disease 
manifestations in swine including respiratory disease and wasting syndrome in growing pigs 
and reproductive failure in breeding herds (Gillespie et al., 2009). In addition, PCV2 is 
transmitted by both horizontal and vertical routes. Horizontal transmission has been shown to 
occur through presence of viable PCV2 in secretions and excretions (Patterson et al., 2010a). 
Vertical transmission has been shown to occur in-utero from the dam to the fetus (Madson et 
al., 2011).  
Several commercial and experimental vaccines have been developed in an attempt to 
prevent PCV-associated disease (PCVAD) in animals. PCV2 infection of dams via artificial 
insemination of spiked semen has been shown to result in dam viremia, fetal infections, and 
increased numbers of mummified and still-born fetuses (Madson et al., 2009b). Despite the 
fact that commercially available vaccines for use in breeding animals are currently not 
available in the United States, vaccination of dams with a single dose of Ingelvac® 
CircoFLEX™  prior to artificial insemination with spiked semen was not effective in 
preventing vertical transmission of PCV2 (Madson et al., 2009a). The previous work only 
used one product in a one dose application. In growing pigs, minor differences between one 
and two dose administrations in preventing PCV2 infection have been detected (Shen et al., 
2010b) and this may be similar in sows and their fetuses. Additionally, no group had yet 
determined the safety and efficacy of an experimental live vaccine in breeding age females. 
Thus, the main objectives of our first study were to determine if different PCV2 vaccines and 
dose administrations could decrease or prevent PCV2 infection in sows. In addition, we 
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wanted to determine if any vaccination regimen was able to decrease or even prevent vertical 
transmission of PCV2.  
In experimentally infected growing pigs, PCV2 viremia is detectable for up to 140 
days (Opriessnig et al., 2010b), has been shown to be shed for up to 70 days post-infection in 
some secretions (Shibata et al., 2003; Patterson et al., 2010b) and was transmissible when 
infected pigs were comingled with naïve contact animals 42 days post-challenge (Bolin et al., 
2001). Despite several studies showing presence of PCV2 in secretions and successful 
horizontal transmission of PCV2 between infected and  naïve contact pigs, no study had yet 
determined if chronically PCV2 infected animals can transmit PCV2 to naïve contact pigs 
and if vaccination is beneficial in this scenario. Additionally, the safety of an experimental 
live vaccine, and its ability to prevent PCV2 transmission to contact pigs, has not been 
evaluated for more than 21 days post challenge (Opriessnig et al., 2011a; Beach et al., 2010). 
Therefore, the main objectives of our second study were to determine if PCV2 could be 
spread to naïve contact animals 140 days after PCV2 challenge, if vaccination with an 
inactivated or experimental-live vaccine is beneficial, and if the live vaccine is transmitted 
168 days post-vaccination to naïve pigs.  
The results from this thesis indicate that vaccination of pigs with an attenuated live 
chimeric PCV1-2 vaccine induced significantly lower levels of PCV2-specific antibodies and 
had delayed development in comparison to the inactivated adjuvanted vaccine version. 
Vaccine viremia was not detected in any of our dams, but low levels of PCV1-2 were 
detected in a few fetuses. Similarly, vaccination of growing pigs with the attenuated live 
chimeric PCV2 vaccine resulted in PCV1-2 viremia in individual vaccinated animals at 
single days indicating that the live vaccine could be safe for use in breeding and finishing 
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herds. In addition, vaccination of sows and growing pigs prior to PCV2 challenge led to 
decreased PCV2 viremia which was independent of vaccine type used (live or inactivated) or 
number of doses administered, indicating that despite lower levels of PCV2-specific 
antibodies with the attenuated live chimeric PCV2 vaccine, both vaccines were effective. In 
addition, vaccination with the attenuated live chimeric PCV1-2 vaccine led to decreased 
prevalence of PCV2 DNA in piglets born to vaccinated animals in comparison to the 
inactivated chimeric PCV1-2 vaccine. 
The results of the first study also further verify that dam vaccination prior to 
challenge does not prevent in-utero spread of PCV2 to fetuses, but resulted in reduced levels 
of PCV2 viremia in sows and fetuses. Additionally, by closing an infected swine population 
for 140 days, under the conditions of the second study, the animal immunity was stabilized, 
preventing the spread of PCV2 to the contact animals in all groups. Unfortunately, the 
infectivity of PCV2 potentially present in the environment could not be determined as the 
PCV2 infected pigs were moved to clean rooms shortly before comingling with the contact 
pigs.  
While these studies are able to provide evidence of decreased viremia in vaccinated 
animals, both areas need to be studied further to further determine the result of vaccination 
on persistence and spread of PCV2 among animal populations. A reproductive study with 
more pregnant dams could provide important confirmation that PCV2 vaccination can indeed 
decrease reproductive failure. A growing pig study with larger sample sizes and without 
moving resident animals prior to the addition of contact animals could provide more clarity 
on the effect of closing a pig population for a long period (140 days) after PCV2 exposure on 
the viability of PCV2 in chronically infected pigs and the environment. They could both add 
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important knowledge for the management of swine herds and could lead to better 
management/prevention practices for decreasing PCV2 infections in breeding and finishing 
herds. 
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